Evidence map›Paper›PMID 33990702›Full record

ArticleBone marrow transplantation2021

Impact of the combination of donor age and HLA disparity on the outcomes of unrelated bone marrow transplantation.

Sachiko Seo, Yoshiaki Usui, Keitaro Matsuo, Yoshiko Atsuta, Aiko Igarashi, Takahiro Fukuda, Yukiyasu Ozawa, Yuta Katayama, Shuro Yoshida, Naoyuki Uchida and 11 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 20 institutions in 2 countries.

Sachiko Seo *Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan. sseo-tky@umin.ac.jp.ORCID http://orcid.org/0000-0002-4308-2152
Yoshiaki Usui *Division of Cancer Information and Control, Aichi Cancer Center Research Institute, Aichi, Japan.ORCID http://orcid.org/0000-0001-6180-0704
Keitaro MatsuoDivision of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Aichi, Japan.ORCID http://orcid.org/0000-0003-1761-6314
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan.ORCID http://orcid.org/0000-0003-4404-2870
Aiko IgarashiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Yukiyasu OzawaDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Yuta KatayamaDepartment of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.ORCID http://orcid.org/0000-0001-5054-9104
Shuro YoshidaDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations, Toranomon Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-5952-5926
Tadakazu KondoDepartment of Hematology and Oncology, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-8959-6271
Shinichi KakoDivision of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.ORCID http://orcid.org/0000-0002-2635-3395
Nobuhiro TsukadaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Shunichi KatoDepartment of Innovative Medical Science, Tokai University School of Medicine, Kanagawa, Japan.
Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Tatsuo IchinoheDepartment of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.ORCID http://orcid.org/0000-0002-0393-4066
Fumihiko KimuraDivision of Hematology, National Defense Medical College, Tokorozawa, Japan.ORCID http://orcid.org/0000-0001-6223-9904
Yoshinobu KandaDivision of Hematology, Jichi Medical University, Tochigi, Japan.ORCID http://orcid.org/0000-0002-4866-9307
Koichi MiyamuraDepartment of Hematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Junya KandaDepartment of Hematology and Oncology, Kyoto University, Kyoto, Japan.ORCID http://orcid.org/0000-0002-6704-3633
JSHCT Donor Source Working Group
Kyoto University · JPJichi Medical University · JPTokai University · JPTokyo Metropolitan Komagome Hospital · JPNagoya University Hospital · JPNational Defense Medical College · JPAichi Cancer Center · JPKonan Kosei Hospital · JPNational Hospital Organization · JPNovartis (Japan) · JPTokyo Medical University Hospital · JPYokohama City University Hospital · JPEuropean Organisation for Rare Diseases · FRHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPImamura Hospital · JPJapanese Red Cross Society, Japan · JPKanagawa Prefectural Hospital Organization · JPKanazawa University Hospital · JPKobe University Hospital · JPKyushu University Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Impact of donor age considering HLA disparity on hematopoietic cell transplantation (HCT) outcomes has not been fully evaluated. We evaluated 8486 patients who received unrelated bone marrow transplantation (UR-BMT) from 8/8 or 7/8 HLA-matched donors. Compared to 8/8 HLA-matched younger donors (<40 years), 8/8 HLA-matched older donors (subdistribution hazard ratio [SHR], 1.16; 95% CI, 0.97-1.38) and 7/8 HLA-matched younger donors (SHR, 1.33; 95% CI, 1.11-1.58) were associated with increased risk of grade III-IV acute graft-versus-host disease (aGVHD). 7/8 HLA-matched older donors had further increased risk (SHR, 2.00; 95% CI, 1.68-2.38) due to interaction between donor age and HLA disparity (p for interaction = 0.038). Progression-free survival (PFS) after UR-BMT with 8/8 HLA-matched younger donors was comparable to that after UR-BMT with 8/8 HLA-matched older donors, whereas UR-BMT with 7/8 HLA-matched younger or older donors was significantly associated with lower PFS than UR-BMT with 8/8 HLA-matched younger donors (younger donor; HR, 1.12; 95% CI, 1.04-1.21, older donor; HR, 1.28; 95% CI, 1.17-1.40; p for interaction = 0.079). In conclusion, adverse effect of increased donor age requires attention, especially in HLA-mismatched UR-BMT due to interaction between donor age and HLA disparity. Intensive aGVHD prophylaxis may be required to improve outcomes after HCT with mismatched older donors.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationBone Marrow TransplantationHumansProportional Hazards ModelsTissue Donors

Identifiers

PMID33990702
OpenAlexW3163589949

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.